Sleep Apnea in Women: The Underdiagnosed Cardiac Risk Factor

When most people picture someone with obstructive sleep apnea (OSA), they picture a middle-aged man who snores loudly, stops breathing during the night, and wakes up exhausted. That picture is accurate for many men. It is not accurate for most women with OSA, and that mismatch has quietly allowed a significant cardiovascular risk factor to go undetected in millions of women for decades.

The evidence shows that OSA in women is underdiagnosed, underreferred, and undertreated at nearly every stage of the clinical pipeline. The consequences fall squarely on the heart: incident hypertension, coronary artery disease, heart failure, and atrial fibrillation have all been linked to OSA in women in large-scale epidemiological studies. Understanding why women present differently, why menopause is a critical inflection point, and how cardiac risk accumulates over time is essential for anyone managing cardiovascular health in women.

How Women Present With OSA: A Different Symptom Cluster

The classic male presentation of OSA is loud snoring, witnessed apneas reported by a bed partner, and excessive daytime sleepiness. Women with OSA frequently present with a distinct and less recognizable symptom cluster.

Research consistently shows that women with OSA are more likely to report fatigue rather than sleepiness. The distinction matters clinically because fatigue is diffuse, nonspecific, and easily attributed to other causes, such as anemia, thyroid disease, depression, or, especially in midlife women, hormonal changes. Women are also more likely to report insomnia, which can further mislead clinicians into pursuing sleep-onset or sleep-maintenance pathways rather than considering a breathing disorder as the primary problem.

Morning headaches, nocturia, and symptoms of depression or anxiety round out the typical female OSA presentation. These symptoms are common across many conditions, and without an index of suspicion specifically for OSA, they rarely prompt a sleep study referral.

Mood symptoms deserve particular attention. Women with undiagnosed OSA are significantly more likely to carry diagnoses of depression and anxiety. In some cases, those diagnoses are treating a downstream effect of sleep-disordered breathing rather than a primary psychiatric condition. The repeated nocturnal hypoxia and sleep fragmentation characteristic of OSA can produce or worsen mood disturbance, and treatment of OSA sometimes produces improvement in mood that antidepressants alone did not.

The bed partner history, which anchors male OSA screening, is also less reliable in women for social reasons: women are more likely to sleep alone, or in a separate room, or to have a partner who sleeps soundly and does not observe nighttime breathing patterns. This removes a common referral trigger entirely.

Prevalence Across the Lifespan: The Menopause Inflection Point

OSA prevalence differs substantially between men and women across the lifespan, and understanding that difference helps explain why cardiovascular risk from OSA is concentrated in the postmenopausal period.

Before menopause, OSA is considerably less common in women than in men. Estimates from community-based studies suggest that premenopausal women have OSA prevalence rates roughly one-quarter to one-third those of age-matched men. The prevailing biological explanation centers on the protective effects of female sex hormones, particularly progesterone.

Progesterone is a respiratory stimulant. It acts on central ventilatory drive to increase respiratory rate and tidal volume, which helps maintain upper airway tone during sleep. Estrogen has independent effects on upper airway muscle tone and may also modulate ventilatory control. Together, these hormones create a physiological environment that is substantially more protective against airway collapse during sleep than the hormonal milieu of men.

Menopause removes that protection. The transition through perimenopause into postmenopause involves a steep and sustained decline in both estrogen and progesterone, and OSA prevalence rises sharply in parallel. The evidence shows that postmenopausal women have OSA prevalence rates that approach or match those of men of similar age. Some analyses indicate that menopause itself, independent of aging and weight gain, quadruples the risk of developing OSA.

This convergence of male and female OSA prevalence in midlife has major cardiovascular implications. Postmenopause is already a period of accelerated cardiovascular risk for women, driven by loss of estrogen’s vascular protective effects. When OSA is added to that landscape, the cumulative burden on the cardiovascular system is substantial.

The Sleep Heart Health Study: What the Data Show in Women

The Sleep Heart Health Study (SHHS) is among the most important epidemiological resources for understanding OSA and cardiovascular outcomes across a large, community-dwelling population. The SHHS enrolled more than 6,000 adults and used objective polysomnographic measurement of OSA, which distinguishes it from studies relying solely on self-report or questionnaire-based apnea scoring.

Analyses from the SHHS demonstrated that OSA in women was independently associated with incident hypertension, coronary artery disease, and heart failure over the study follow-up period. 4 / Promising The hazard ratios in women were generally lower than those observed in men, a finding that is sometimes misread as evidence that OSA is less dangerous for women. That interpretation is incorrect. Lower relative hazard ratios in women reflect, in part, a lower baseline event rate; the absolute cardiovascular risk attributable to OSA in postmenopausal women remains clinically meaningful.

An important secondary finding from SHHS analyses concerned hormone replacement therapy. Postmenopausal women who were using HRT at the time of SHHS enrollment had significantly lower rates of OSA compared to postmenopausal women not on HRT, even after adjusting for confounders including BMI. 3 / Early This observational finding does not establish causality and should not be used as the sole rationale for initiating HRT. However, it adds biological plausibility to the hypothesis that the estrogen and progesterone in HRT may partially restore the upper airway protective effects lost at menopause, potentially reducing OSA severity in some women.

Non-Dipping Blood Pressure: A Cardiac Mechanism Specific to Nighttime Physiology

One of the most important cardiovascular consequences of OSA, and one that receives less attention than it deserves in discussions of female cardiac risk, is the disruption of normal nocturnal blood pressure physiology.

Under normal circumstances, blood pressure follows a circadian pattern, falling by 10 to 20 percent during sleep relative to waking levels. This nighttime dip is physiologically important: it gives the heart, arteries, and kidneys a period of reduced hemodynamic stress each night. People who display this normal pattern are called “dippers.”

OSA disrupts this pattern. The repeated apneic episodes cause surges in sympathetic nervous system activity, which drive acute elevations in blood pressure at the moment of apnea termination. Over time, the cumulative effect of hundreds of these nocturnal surges is a sustained attenuation of the normal nighttime BP dip. People with OSA are disproportionately represented among “non-dippers,” individuals whose nocturnal BP does not fall normally, or among “reverse-dippers,” whose BP actually rises during sleep.

Non-dipping blood pressure is an independent predictor of cardiovascular events, including stroke, myocardial infarction, left ventricular hypertrophy, and kidney disease. It is detectable only through ambulatory blood pressure monitoring performed over a 24-hour period, which means that office-based BP measurements will not reveal it. Some cardiologists recommend 24-hour ambulatory BP monitoring in women with suspected or confirmed OSA precisely to identify this pattern.

The evidence shows that non-dipping is more prevalent in women with OSA than in men with OSA, and that the cardiovascular risk associated with non-dipping may be particularly pronounced in women. This makes the combination of female sex, postmenopause status, and OSA a clinically important triad warranting careful hemodynamic assessment.

Heart Rate Variability and Autonomic Dysregulation

OSA exerts its cardiac effects in part through sustained activation of the sympathetic nervous system, and one measurable marker of that activation is reduced heart rate variability (HRV).

HRV refers to the beat-to-beat variation in the time between heartbeats, reflecting the dynamic interplay between sympathetic and parasympathetic influences on cardiac rhythm. High HRV indicates a well-regulated autonomic nervous system with substantial parasympathetic tone. Low HRV indicates sympathetic dominance and blunted parasympathetic responsiveness, and it is a well-established marker of increased cardiac risk.

OSA reduces HRV through a straightforward mechanism: repeated apneic episodes trigger surges in sympathetic activity as the brain attempts to overcome airway obstruction and resume breathing. Over time, chronic nocturnal sympathetic activation bleeds into daytime physiology, resulting in persistently elevated sympathetic tone and attenuated vagal influence. The result is chronically reduced HRV.

The cardiac downstream effects of this sympathetic dysregulation include hypertension through sustained peripheral vasoconstriction and increased cardiac output, endothelial dysfunction through oxidative stress and reduced nitric oxide bioavailability, and an arrhythmia-permissive electrophysiological environment through altered autonomic modulation of cardiac conduction.

In women, the evidence shows that autonomic cardiovascular regulation differs from men at baseline, with greater parasympathetic tone in premenopausal women. The loss of that parasympathetic advantage through OSA-driven sympathetic upregulation may therefore represent a more significant physiological disruption than an equivalent degree of HRV reduction in men.

Atrial Fibrillation Risk in Women With OSA

The relationship between OSA and atrial fibrillation (AF) is one of the most clinically significant links in electrophysiology. OSA is recognized as an independent risk factor for AF, for its first occurrence, for recurrence after cardioversion, and for failure of ablation procedures.

Several mechanisms link OSA to AF. The repeated surges in intrathoracic pressure during obstructed breathing create mechanical stress on the atrial walls. Chronic hypoxia promotes atrial fibrosis. Sympathetic activation from apneic episodes creates the electrical irritability that initiates and perpetuates AF. Inflammation, a shared feature of both OSA and AF, may contribute to the structural remodeling of atrial tissue that makes AF self-sustaining.

The relationship between OSA and AF appears to be particularly strong in women with paroxysmal AF. Some analyses suggest that women with paroxysmal AF have higher rates of undiagnosed OSA than would be expected, and that untreated OSA is associated with higher AF recurrence rates after both pharmacological and procedural management. Some electrophysiologists now recommend OSA screening and treatment as a component of AF management, particularly in women where OSA may be hidden behind a non-classic presentation.

Why Women Are Underreferred: The Diagnostic Gap

Despite the cardiovascular stakes, women are consistently referred less often for sleep studies than men, and when referred, are more likely to be underdiagnosed.

Several factors contribute to this gap. The standard screening tools used in clinical practice were developed and validated primarily in male populations. The Epworth Sleepiness Scale, which asks about likelihood of dozing in various situations, is less sensitive in women because women with OSA more commonly report fatigue rather than sleepiness; they score lower on the Epworth even when their OSA is severe. STOP-BANG, a widely used OSA screening questionnaire, has lower sensitivity in women because it weights snoring, witnessed apneas, and neck circumference, all features more common in male presentations.

The Berlin Questionnaire performs somewhat better in women because it includes a broader range of symptoms. Simply asking about fatigue, morning headaches, nocturia, and insomnia rather than defaulting to sleepiness and snoring can substantially improve case-finding in female patients.

There is also a referral bias at the clinician level. Studies of sleep clinic referral patterns consistently show that women are referred less often than men at equivalent symptom severity, and that when referred, they are more likely to have their study interpreted as normal because AHI cutoffs were established in male-predominant research cohorts.

Treatment: CPAP, Weight, and Other Approaches

Continuous positive airway pressure (CPAP) is the first-line treatment for moderate to severe OSA regardless of sex, and the evidence shows that CPAP is equivalently effective in women and men in terms of AHI reduction and improvement in objective sleep parameters. Where outcomes sometimes differ is in adherence. Some data show that women have lower CPAP adherence than men, which may reflect differences in mask fit (masks have historically been designed around male facial geometry), discomfort with the aesthetics of the device, or social factors around sleeping with a partner.

Addressing these adherence barriers directly, through mask fit improvement, heated humidification to reduce dryness, and regular follow-up, is a practical priority for women starting CPAP.

Weight loss is an effective adjunct for women with OSA who are overweight or obese. Even modest reductions in body weight, in the range of 10 to 15 percent, can produce meaningful reductions in AHI. This is particularly relevant for postmenopausal women, in whom weight gain, especially central adiposity, is common and contributes to pharyngeal fat deposition and increased collapsibility of the upper airway.

Positional therapy, which uses devices or positioning aids to prevent supine sleep, is a reasonable option for women with positional OSA, defined as OSA that is predominantly or exclusively present in the supine position. It is less effective for severe non-positional OSA but may be sufficient for milder cases or as an adjunct to other treatment.

HRT and OSA: Evidence and Caution

The SHHS observational data linking HRT use to lower OSA prevalence in postmenopausal women have prompted ongoing interest in whether hormonal therapy could serve as a partial treatment strategy for OSA in this population.

The biological rationale is plausible: restoring progesterone and estrogen levels could, in theory, partially restore the upper airway protective effects lost at menopause. Small clinical studies show reductions in AHI with HRT use in postmenopausal women with OSA. However, these studies have been limited by small sample sizes and short follow-up, and HRT carries its own risk-benefit profile that must be evaluated for each individual.

Guidelines do not currently recommend initiating HRT solely for OSA management. For women who are already using HRT for menopausal symptom management, the potential additional benefit of reduced OSA severity may be a relevant consideration. Any HRT discussion should involve shared decision-making that accounts for the individual’s cardiovascular risk profile, breast cancer risk, and personal preferences.

Putting It Together: A Cardiac Risk Framework for OSA in Women

Clinicians caring for women’s cardiovascular health benefit from integrating OSA into their risk assessment framework, particularly for perimenopausal and postmenopausal patients.

A woman presenting with fatigue, insomnia, morning headaches, nocturia, and worsening blood pressure control deserves consideration of OSA on the differential, even in the absence of snoring. A woman with paroxysmal atrial fibrillation, difficult-to-control hypertension, or unexplained heart failure should be screened for OSA as part of a systematic evaluation. A woman with non-dipping blood pressure on ambulatory monitoring should be specifically queried about sleep symptoms.

The tools needed for better identification are available: broader screening questionnaires, home sleep testing for women who would not tolerate in-lab polysomnography, and a lower threshold for referral when symptoms are present. Treatment with CPAP, when adherence is supported, is effective and can meaningfully reduce the cardiovascular burden of untreated OSA.

The evidence base for OSA as a cardiovascular risk factor in women is substantial. What has lagged is clinical recognition and referral. Closing that gap is a tractable and consequential goal for women’s cardiac care.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.